key: cord-0695340-6kgc3chd
authors: Chang, Stephanie H.; Chen, David; Paone, Darien; Geraci, Travis C.; Scheinerman, Joshua; Bizekis, Costas; Zervos, Michael; Cerfolio, Robert J.
title: Thoracic Surgery Outcomes for Patients with Coronavirus Disease 2019 (COVID-19)
date: 2021-01-30
journal: J Thorac Cardiovasc Surg
DOI: 10.1016/j.jtcvs.2021.01.069
sha: 45ed3a4b63c51581906bd6cad0c6821dc2082738
doc_id: 695340
cord_uid: 6kgc3chd

Objective As the COVID-19 pandemic continues, appropriate management of thoracic complications from COVID-19 needs to be determined. Our objective is to evaluate which complications occur in patients with COVID-19 require thoracic surgery, and report early outcomes. Methods This study is a single-institution retrospective case series at New York University Langone Health Manhattan campus evaluating patients with confirmed COVID-19 infection who were hospitalized and required thoracic surgery from March 13th—July 18th, 2020. Results From March 13th—August 8th, 2020, 1,954 patients were admitted to our hospital for COVID-19. Of these patients, 13 (0.7%) required thoracic surgery. Two (15%) patients required surgery for complicated pneumothoraces, five (38%) patients underwent pneumatocele resection, one (8%) patient had an empyema requiring decortication, and five (38%) patients developed a hemothorax that required surgery. Three (23%) patients died after surgery, nine (69%) patients were discharged, and one (8%) patient remains in the hospital. No healthcare providers converted to COVID-19 positive after the surgeries. Conclusions Given the 77% survival rate, with a majority of patients already discharged from the hospital, thoracic surgery is feasible for the small percent of patients hospitalized with COVID-19 who underwent surgery for complex pneumothorax, pneumatocele, empyema, or hemothorax. Our experience also supports the safety of surgical intervention for healthcare providers who operate on patients with COVID-19.

ARDS caused by COVID-19 often leads to a reduction in lung compliance 4 . Due to the 80 high peak end expiratory pressure required to ventilate patients, as well as distinct pulmonary 81 pathology 5 , patients with COVID-19 have a higher incidence of barotrauma compared to patients 82 with ARDS from other causes 6 . Other patients with COVID-19 develop pneumatoceles 7 , which 83 are thin-walled air-filled cysts in the lung parenchyma that are sequela of pneumonia 8 . 84

Hypercoagulability is common in patients with COVID-19, with many patients 85 expressing elevated D-dimer levels and sustaining a high incidence of arterial thrombosis, 86 pulmonary embolism, and often mortality attributed to thromboembolic complications 1 . Though 87 guidelines regarding anticoagulation vary, the high rate of thrombosis has led to some critically 88 ill patients with COVID-19 being placed on therapeutic anticoagulation 9 . Additionally, some 89 patients with COVID-19 may require further respiratory support, such as veno-90 venous extracorporeal membrane oxygenation (VV-ECMO) 10 , which is another indication for 91

The potential consequences of barotrauma, pneumatoceles, and therapeutic 93 anticoagulation are pulmonary or pleural complications that may require surgical intervention. 94

Little data is reported regarding the need for and efficacy of thoracic surgery for sequela of 95 COVID-19. The primary purpose of this study is to evaluate what complications develop in 96 patients with COVID-19 that require thoracic surgery at a tertiary hospital in New York City. 97

We also will describe the operations performed and early outcomes for these patients, and 98 evaluate the safety of performing thoracic surgery operations for healthcare providers. 99 100

This study is a single-institution retrospective case series evaluating all patients who were 103 positive for COVID-19, admitted to the hospital at New York University Langone Health 104 (NYULH) Manhattan campus, and underwent thoracic surgery between March 13 th , 2020 (the 105 time of our first admission) to August 8 th , 2020. Data collection was performed on September 106 8 th , 2020 to allow for 30-day follow up. Patients were deemed positive for COVID-19 by 107 reverse transcriptase polymerase chain reaction (rtPCR). Thoracic surgery was defined as any 108 procedure performed in the operating room that involved the thoracic cavity, including pleural 109 procedures and pulmonary resection. All patients with COVID-19 requiring thoracic surgery 110 were included. There were no exclusion criteria, though each patient was assessed by a thoracic 111 surgeon, who determined the need for surgical intervention. The NYULH institutional review All patients with clinically significant pneumothoraces underwent tube thoracostomy. 117

For patients with a chest tube and non-resolving air leaks after 2 weeks that could not tolerate 118 water seal underwent a chest computed tomography (CT) to further evaluate their pleural space 119 and lung parenchyma, and evaluated for thoracic surgery. Additionally, patients with chest tubes 120 and continued large pneumothorax were evaluated for surgical management. 121

Patients who were febrile with a loculated empyema were evaluated for empyema 122 evacuation and decortication. All patients with a loculated hemothorax that was still present 123 after tube thoracostomy were evaluated for possible hemothorax evacuation and decortication. 124

Furthermore, all patients with worsening respiratory status or hypotension secondary to active 125 bleeding or expanding pneumothorax despite chest tube placement were also taken to the 126 operating room for management. Outcomes 141

The primary outcome for this study is to report the incidence and describe the 142 complications of COVID-19 that required thoracic surgery. The secondary outcomes for this 143 study are the early outcomes from the operations, and healthcare provider safety, defined as 144 freedom from conversion from a negative to positive COVID-19 rtPCR test. All healthcare 145 providers were screened for COVID-19 symptoms (fever, cough, shortness of breath, chills, 146 myalgia, diarrhea, and headaches), and all underwent rtPCR testing on a monthly basis. 147 148

Patients who underwent thoracic surgery 150

From March 13 th , 2020 to July 18 th , 2020, 1,899 patients with a positive rtPCR test for 151 COVID-19 were admitted to our Manhattan Tisch Hospital. During this time period, 13 patients 152 (0.7%) who were hospitalized for COVID-19 underwent thoracic surgery. All 13 (100%) 153 patients were male; patient characteristics are summarized in Table 1 . 154 155

Among thirteen patients, 17 operations were performed. Two patients (15%) had 157 multiple operations due to ongoing bleeding. Of the 17 operations, 10 (61%) were performed in 158 a minimally invasive fashion, which accounts for the operations in 10 (77%) of the 13 patients. 159

Of the 3 patients that required thoracotomy, two patients were operated on for ongoing 160 hemorrhage with hemodynamic instability and one patient had acute respiratory distress during 161 induction (Table 2) . Regarding efficacy of surgery for bleeding, the only patient in this group that died 255 postoperatively was > 70 years old, with acute renal failure, a stroke and cardiac arrest 256 previously during his hospital stay. Due to the patient's large hemothorax with inability to wean 257 from the ventilator, surgery was performed. However, given his age and comorbidities, the 258 postoperative liver failure and resultant mortality is likely due to patient specific factors. The 259 remaining four patients (80%) have all been discharged, indicating that surgery for bleeding in 260

A secondary finding in this report is the rate of incidental lobar and sub-lobar necrosis 262 present in 31% (n=4) patients, though only 1 (7.7%) patient had complete lobar necrosis. While 263 hypercoagulability, with resultant strokes 16, 17 and myocardial ischemia 18,19 , have been described 264 in COVID-19, no such report exists for lung necrosis. Despite three of the four patients being on 265 therapeutic anticoagulation prior to surgery, pulmonary necrosis was present and necessitated 266 resection, indicating a microvascular disease process that may be refractory to anticoagulation. 267

Pathology of autopsy specimens indicates that microthrombus and large vessel thrombus was 268 present in a cohort of patients with a median age of 73, and 60% of patients having greater than 3 269 comorbidities 5 , though rate of anticoagulation in those patients was not reported. Additional 270 pathologic evaluation of these resected necrotic pulmonary specimens is necessary to further 271 elucidate the mechanism of pulmonary injury in patients with COVID-19. Interestingly, no 272 pulmonary necrosis was evident on preoperative imaging for any patient. The major strength of this series is that it is the largest case series describing 287 complications of COVID-19 that require thoracic surgical intervention, and reports early 288 outcomes. Additionally, this report demonstrates the feasibility of operating on patients with 289 COVID-19 without transmission of the disease to healthcare workers. This study is limited as it 290 is a single-institution retrospective analysis. Furthermore, data regarding the total number of 291 patients who were evaluated for and declined for surgical intervention are not available due to 292 the retrospective nature of this study. Operating room staff wearing personal protective equipment during thoracic surgery on a patient 386 with COVID-19. All non-sterile personnel are wearing a gown, gloves, eye protection, N-95, 387 and hair cover. All sterile personnel are wearing the standard sterile gown, sterile gloves, eye 388 protection, and hair cover, with the use on an N-95 mask versus a standard operating room mask. 389 

Risk of ischemic stroke 337 in patients with coronavirus disease 2019 (COVID-19) vs patients with influenza 338

Clinical characteristics and 340 outcomes of COVI-19 patients with a history of stroke in Wuhan

Association of cardiac injury with 343 mortality in hospitalized patients with COVID-19 in Wuhan, China

Cardiovascular implications of fatal 346 outcomes of patients with Coronavirus Disease 2019 (COVID-19)

COVIDSafe thoracic surgery: minimizing intraoperative 349 exposure to the aerosols

COVID-19: Safe thoracic 351 surgery